An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

This publication has 14 references indexed in Scilit:

• Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects
  British Journal of Clinical Pharmacology, 2003
• Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers
  British Journal of Clinical Pharmacology, 2002
• Liver-Specific Distribution of Rosuvastatin in Rats: Comparison with Pravastatin and Simvastatin
  Drug Metabolism and Disposition, 2002
• The effect of fluconazole on the pharmacokinetics of rosuvastatin
  European Journal of Clinical Pharmacology, 2002
• No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor
  The Journal of Clinical Pharmacology, 2002
• Optimizing the pharmacology of statins: characteristics of rosuvastatin
  Atherosclerosis Supplements, 2002
• Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia
  Published by Elsevier ,2002
• Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
  The American Journal of Cardiology, 2001
• Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C
  Atherosclerosis Supplements, 2001
• Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat
  Atherosclerosis, 2000